Ubiquinol for tiredness and muscle strength in adults taking GLP-1 weight loss medicines
Tests ubiquinol against placebo for fatigue and muscle strength in adults using GLP-1 medicines.
Plain-language title generated from the registry record
Registry title: A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists
Key facts
- Where
- Glasgow, United KingdomSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 30-65 who recently started Wegovy or Mounjaro for weight loss. It tests whether ubiquinol lowers fatigue and helps keep muscle strength.
- Age
- 30 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Body mass index above 27 and below 35 kg/m2. Must be able to do at least one sit-to-stand movement.
- Earlier treatment
- Must be starting, or have started within the last 16 weeks, semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) for weight management. Must not have used ubiquinol or Co-enzyme Q10 in the last 3 months, any statin, or other GLP-1 agonists before, or had bariatric surgery.
- Biomarker or test result
- Screening blood results must be within the lab reference range.
Main reasons for not taking part
- Another condition that may affect fatigue, such as diabetes, heart disease, sleep apnoea, autoimmune disease, advanced liver disease or cancer
- Current or past use of statin medication
- Earlier use of GLP-1 agonists or bariatric surgery
- Plan to stop the GLP-1 medicine within 9 months
- Pregnancy, breastfeeding or plan to conceive during the study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT07789106, who can take part
Where in United Kingdom
- Office 1110 3 Fitzroy Place, 1/1, Sauchiehall StreetGlasgow, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- StudySetGo
- Trial code
- NCT07789106
- Record updated
- 19 October 2026
- Original description
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are:Read full original descriptionShow less
A Randomised, Placebo-Controlled Trial to Evaluate the Effect of Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Who Are Self-Administering GLP-1 Agonists ("Project Zest")
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are:
Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment?
Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications.
Participants will:
Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test. Attend a short monthly video call (about 20-30 minutes) with a study dietitian. Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app. Log all exercise sessions in the smartphone app throughout the study.
This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.
Inclusion: Age 30-65 years; Body mass index >27kg/m2 and <35 kg/m2; Currently initiating, or has initiated within the preceding 16 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management; Is physically mobile and able to complete at least one sit to stand movements; Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app; Proficient in English language speaking and reading; Owns their own digital body weighing scale; Able and willing to provide full informed consent.
Exclusion: Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening; Prior or current use of statin medication; Has previously used GLP-1 agonists and/or undergone bariatric surgery; Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10; Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy); Failed screening bloods (any results that is outside of the lab reference range); Intention to stop GLP-1 agonist use within 9 months of randomisation; Pregnancy, breastfeeding or intention to conceive during study.